HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Monoamine oxidase inhibitor therapy for anorexia nervosa and bulimia: a preliminary trial of isocarboxazid.

Abstract
In an open prospective clinical study, 14 female outpatients with anorexia nervosa or bulimia completed a 6-week trial of isocarboxazid, with a mean dose of 34 mg. The eight bulimic and six restrictive anorexic subjects did not show any significant differences in medication response. Ratings of depression and anxiety showed significant improvement after the fourth week. Significant improvement in eating behavior, as measured by the number of meals missed per day, was noted. For the bulimic subgroup, bingeing and vomiting showed a nonsignificant reduction, while the urge to binge was significantly reduced. There was no significant weight change in either group during the study, although the restrictive group had gained substantially at 6-month follow-up.
AuthorsS H Kennedy, N Piran, P E Garfinkel
JournalJournal of clinical psychopharmacology (J Clin Psychopharmacol) Vol. 5 Issue 5 Pg. 279-85 (Oct 1985) ISSN: 0271-0749 [Print] United States
PMID3862680 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Isocarboxazid
Topics
  • Adolescent
  • Adult
  • Anorexia Nervosa (complications, drug therapy)
  • Attitude to Health
  • Body Weight
  • Depressive Disorder (complications)
  • Feeding and Eating Disorders (drug therapy)
  • Female
  • Humans
  • Hyperphagia (complications, drug therapy)
  • Isocarboxazid (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: